menu
    • menu
    [{"orgOrder":0,"company":"Bioclinica","sponsor":"Direct Biologics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"DB-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bioclinica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bioclinica \/ Direct Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bioclinica \/ Direct Biologics"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SLN360","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medpace, Inc \/ Medpace","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Cinven Partners LLP

    Menu

    Cinven Partners LLP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sevasemten

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Edgewise Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 i...

                            Details : EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.

                            Brand Name : EDG-5506

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2023

                            Lead Product(s) : Sevasemten

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Edgewise Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etripamil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Milestone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spra...

                            Details : MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.

                            Brand Name : MSP-2017

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2022

                            Lead Product(s) : Etripamil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Milestone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Medpace, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLN360

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Silence Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to Hi...

                            Details : This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.

                            Brand Name : SLN360

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 17, 2021

                            Lead Product(s) : SLN360

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Silence Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bioclinica

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Bioclinica

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DB-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Direct Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bioclinica Partners with Direct Biologics to Provide Interactive Response Technology (IRT) Solution for COVID-...

                            Details : Under the terms of the agreement, Direct Biologics will leverage Bioclinica’s Interactive Response Technology (IRT) for their EXIT COVID-19 study, a multi-center FDA phase II clinical trial for the use of ExoFlo™ to treat COVID-19 acute respiratory d...

                            Brand Name : ExoFlo

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 09, 2020

                            Lead Product(s) : DB-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Direct Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth